We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quotient Clinical Showcases Enabled-First-in-Human® Programs at ASCPT 2016
Product News

Quotient Clinical Showcases Enabled-First-in-Human® Programs at ASCPT 2016

Quotient Clinical Showcases Enabled-First-in-Human® Programs at ASCPT 2016
Product News

Quotient Clinical Showcases Enabled-First-in-Human® Programs at ASCPT 2016


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Quotient Clinical Showcases Enabled-First-in-Human® Programs at ASCPT 2016"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

As part of the event, Quotient Clinical will be hosting a seminar entitled Accelerating timelines from candidate selection to proof-of-concept with Enabled-FIH programs. This seminar will cover unique and innovative approaches to reaching proof-of-concept (POC), with presentations from Hazel Hunt, VP of Research at Corcept Therapeutics, and Alyson Connor, Executive Director of Exploratory Clinical Pharmacology at Quotient Clinical. The speakers will describe integrated and adaptive clinical protocols which combine healthy volunteer and POC investigations, with case studies to highlight the benefits of using real-time, adaptive GMP manufacturing to adjust drug dose and product composition in response to emerging clinical data.

Alyson Connor commented: “Our Enabled-First-In-Human service is playing a key role in helping our clients to accelerate their early development timelines and achieve significant cost savings. Overall, we believe our service represents an important step forward in solving industry challenges and helping to improve R&D productivity.”

Advertisement